CLINICAL TRIALS PROFILE FOR ZAROXOLYN
✉ Email this page to a colleague
All Clinical Trials for ZAROXOLYN
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00649051 ↗ | Fasting Study of Metolazone Tablets 2.5 mg and Zaroloxyn® Tablets 2.5 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2002-12-01 | The objective of this study was to investigate the bioequivalence of Mylan metolazone 2.5 mg tablets to Celltech Zaroxolyn® 2.5 mg tablets following a single, oral 10 mg (4 x 2.5 mg) dose administration under fasting conditions. |
NCT00649181 ↗ | Fasting Study of Metolazone Tablets 5 mg and Zaroloxyn® Tablets 5 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2003-10-01 | The objective of this study was to investigate the bioequivalence of Mylan metolazone 5 mg tablets to Celltech Zaroxolyn® 5 mg tablets following a single, oral 10 mg (2 x 5 mg) dose administration under fasting conditions. |
NCT00650195 ↗ | Fasting Study of Metolazone Tablets 10 mg and Zaroloxyn® Tablets 10 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2004-02-01 | The objective of this study was to investigate the bioequivalence of Mylan metolazone 10 mg tablets to Celltech Zaroxolyn® 10 mg tablets following a single, oral 10 mg (1 x 10 mg) dose administration under fasting conditions. |
NCT00904488 ↗ | Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure | Terminated | University of Illinois at Chicago | Phase 4 | 2008-10-01 | The purpose of this prospective, randomized, open-label study is to compare two diuretic strategies in patients with acute decompensated heart failure (ADHF): the addition of an oral thiazide diuretic to intravenous bolus (IVB) loop diuretic will be compared to transition from IVB to continuous infusion (CI) loop diuretic. |
NCT00904488 ↗ | Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure | Terminated | Virginia Commonwealth University | Phase 4 | 2008-10-01 | The purpose of this prospective, randomized, open-label study is to compare two diuretic strategies in patients with acute decompensated heart failure (ADHF): the addition of an oral thiazide diuretic to intravenous bolus (IVB) loop diuretic will be compared to transition from IVB to continuous infusion (CI) loop diuretic. |
NCT00904488 ↗ | Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure | Terminated | University of North Carolina, Chapel Hill | Phase 4 | 2008-10-01 | The purpose of this prospective, randomized, open-label study is to compare two diuretic strategies in patients with acute decompensated heart failure (ADHF): the addition of an oral thiazide diuretic to intravenous bolus (IVB) loop diuretic will be compared to transition from IVB to continuous infusion (CI) loop diuretic. |
NCT02606253 ↗ | Comparison of Oral or Intravenous Thiazides vs Tolvaptan in Diuretic Resistant Decompensated Heart Failure | Completed | Vanderbilt University | Phase 4 | 2016-02-01 | Broad Objectives: To determine the comparative efficacy of commonly employed strategies to overcome loop diuretic resistance when added to concomitant loop diuretics in hospitalized decompensated heart failure patients with hypervolemia Specific Aims: 1. Compare the 48-hour weight change of either intravenous chlorothiazide or oral tolvaptan compared to standard-of-care oral metolazone when combined with standardized loop diuretic dosing for diuretic resistance in decompensated heart failure 2. Compare the adverse effects of electrolyte depletion and renal function changes between intravenous chlorothiazide or oral tolvaptan compared to standard-of-care oral metolazone when combined with standardized loop diuretic dosing for diuretic resistance in acute heart failure 3. Pharmacoeconomic analysis of the direct costs of intravenous chlorothiazide or oral tolvaptan compared to standard-of-care oral metolazone when combined with standardized loop diuretic dosing for diuretic resistance in acute heart failure The investigators will conduct a dual center, randomized, double-blind, double-dummy, parallel design trial comparing: oral metolazone, intravenous chlorothiazide, or oral tolvaptan, in combination with loop diuretics in 60 patients hospitalized for hypervolemic decompensated heart failure and displaying loop diuretic resistance. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ZAROXOLYN
Condition Name
Clinical Trial Locations for ZAROXOLYN
Trials by Country
Clinical Trial Progress for ZAROXOLYN
Clinical Trial Phase
Clinical Trial Sponsors for ZAROXOLYN
Sponsor Name